Metabolic support of antiviral therapy in patients with COVID-19
https://doi.org/10.31146/1682-8658-ecg-199-3-143-149
Abstract
Remaxol was evaluated as a means of hepatotropic support for patients with COVID-19 receiving antiviral therapy. Patients were observed in two groups of 30 people each and received intravenous infusions of Remaxol (400.0 ml) or “active placebo” (400.0 ml. 0.9% sodium chloride) for 10 days. In these groups of patients, an analysis was made of the dynamics of clinical parameters and laboratory tests that characterize the functionality of the liver. The results of the analysis made it possible to state that the use of the corrector of cellular and energy metabolism metabolism Remaxol as a hepatoprotector in complex therapy contributes to favorable clinical dynamics, stabilization of biochemical parameters of liver function and allows completing the course of etiotropic therapy in all patients.
Good tolerability of the drug “Remaxol” and the absence of pronounced side effects were noted. The course of Remaxol made it possible to carry out therapy with antiviral agents without dose adjustment and duration of treatment.
About the Authors
A. A. Shuldyakov
Saratov state medical University named after V.I. Razumovsky
Russian Federation
Russian Federation
Andrey A. Shuldyakov -MD, PhD, DSc (Medicine), Head of the Department of Infectious Disease; professor of the Department of Infectious Disease, Scopus Author ID: 35622415500, ResearcherID: U-5598–2017.
112, Bolshaya Kazachya street, Saratov, 410012
E. P. Lyapina
Saratov state medical University named after V.I. Razumovsky
Russian Federation
Russian Federation
Elena P. Lyapina -MD, PhD, DSc (Medicine), professor of the Department of Infectious Disease. Scopus Author ID: 55944019300, Web of Science ResearcherID: AAD-3436–2021.
112, Bolshaya Kazachya street, Saratov, 410012
A. N. Smagina
Saratov state medical University named after V.I. Razumovsky
Russian Federation
Russian Federation
Anna N. Smagina -MD, PhD (Medicine), Associate Professor of the Department of Infectious Disease, Scopus Author ID: 37035051700.
112, Bolshaya Kazachya street, Saratov, 410012
O. B. Lisko
Saratov state medical University named after V.I. Razumovsky
Russian Federation
Russian Federation
Olga B. Lisko -MD, PhD (Medicine), Associate Professor of the Department of Infectious Disease; Scopus Author ID: 1612131556229, Web of Science ResearcherID: AAD-8243–2021.
112, Bolshaya Kazachya street, Saratov, 410012
References
1. Yushchuk N.D., Vengerov Yu. Ya. Infektious Diseases. Moscow: GEOTAR-Media, 2021; 1104 P. (In Russ.) doi: 10.33029/9704–6122–8-INB-2021–1–1104
2. Interim guidelines: prevention, diagnosis and treatment of novel coronavirus infection (COVID-19). Version 11 (05/07/2021). (In Russ.) Available: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/055/735/original/BMP Access: 15.01.2021.
3. Palella F. J. Jr, Baker R. K., Moorman A. C., et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J. Acquir Immune Defi c Syndr. 2006; 43:27-34. doi: 10.1097/01.qai.0000233310.90484.16
4. Smith C., Sabin C. A., Lundgren J. D., et al. Factors associated with specifi c causes of death amongst HIVpositive individuals in the D: A: D Study. AIDS. 2010; 24:1537-1548. doi: 10.1097/QAD.0b013e32833a0918
5. Temirbulatov I.I., Kryukov A. V., Sychev D. A. Pharmacogenetics of antiviral agents for the treatment of COVID-19. Pharmacogenetics and Pharmacogenomics. 2021; 1: 38–41. (In Russ.) doi:10.37489/2588–0527-2021–1–38–41
6. Ilchenko L. Yu., Nikitin I. G., Fedorov I. G. COVID-19 and liver damage. Th e Russian Archives of Internal Medicine. 2020; 3(53): 188–197. (In Russ.) doi:10.20514/2226–6704–2020–10–3–188–197
7. Kazyulin A. N. Drug hepatotoxicity in clinical practice. Medical Council. 2012; 9: 37-44. (In Russ.) ID: 18064886
8. Shuldyakov A.A., Rechnik V. N., Soboleva L. A., et al. Improvement of pathogenetic therapy for chronic hepatitis C. Epidemiology and Infectious Diseases. 2009; 3: 18–21. (In Russ.) ID: 12788514.
9. Sologub T.V., Goryacheva L. G., Suchanov D. S., et al. Hepatoprotective activity of remaxol for chronic liver dysfunction (the materials of milticentre randomized clinical study). Clinical medicine. 2010; 88(1):62–66. (In Russ.) ID: 14340100.
10. Kozhoka T. G. Drugs in the pharmacotherapy of cell pathology. Moscow. Shatskaya printing house Publ., 2007. 136 p. (In Russ.) ISBN 978–5–901950–09–8
11. Gupta N.K., Lewis J. H. Review article: the use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Th er. 2008; 28(9): 1021–1041. doi: 10.1111/j.1365–2036/2008/03822/x
12. Matveev A. V., Kiselev Yu. Yu., Sychev D. A. Current and future use of favipiravir in patients with COVID-19. Good Clinical Practice. 2020; 4S:106–114. (In Russ.) doi 10.37489/2588–0519–2020-S4–106–114
13. Nalbandian, A., Sehgal, K., Gupta, A., et al. Post-acute COVID-19 syndrome. Nat Med 2021; 27: 601–615. doi: 10.1038/s41591–021–01283-z
14. Beigel J.H., Tomashek K. M., Dodd L. E., et al. Remdesivir for the treatment of covid-19-fi nal report. N Engl J Med 2020; 383: 1813–1826 doi: 10.1056/NEJMoa2007764
15. Ivnitsky Yu. Yu., Golovko A. I., Sofronov G. A. Succinic acid in the system of metabolic correction of the functional state and resistance of the organism. Saint – Petersburg. Lan Publ., 1998. 82 p (In Russ.) ID: 29871752.
16. Tikhonova E.O., Lyapina E. P., Shuldyakov A. A., et al. Use of succinate-containing agents in the treatment of infectious diseases. Th erapeutic archive. 2016; 11: 121–127. (In Russ.) doi: 10.17116/terarkh20168811121–127
17. Sologub T.V., Romantsov M. G., Shuldyakov A. A., et al. Reambirin as the medicine of pathogenetical therapy of acute and chronic viral liver dysfunction. Clinical medicine. 2010; 4: 68–71. (In Russ.) ID: 15198305.
18. Tikhonova E.O., Lyapina E. P., Shuldyakov A. A., et al. Reamberin in the complex therapy of acute intestinal infections. Experimental & clinical gastroenterology. 2017; 2(138): 77-85. (In Russ.) ID:28870089.
19. Shuldyakov A.A., Lyapina E. P., Soboleva L. A., et al. Th e use of cytofl avin for the treatment of chronic brucellosis. Clinical medicine. 2011; 2: 56–58. (In Russ.) ID: 16380454.
20. Tikhonova E.O., Lyapina E. P., Shuldyakov A. A. Efficacy of Pathogenetic Th erapy in Patients with Acute Gastrointestinal Infections Using Succinic Acid Derivatives (Reamberin). Experimental and clinical pharmacology. 2013; 76(1): 11–13. (In Russ.) ID:22392298.
21. Kolokolov O.V., Shuldyakov A. A., Bakulev A. L. Neuroprotective and metabolic support of antimicrobial therapy in patients with neurosyphilis. Infectious diseases. 2020; 18(3):159–166 (In Russ.) doi: 10.20953/1729–9225– 2020–3–159–166
22. State Register of Medicinal Products. Ministry of Health State Register of Medicines Publ. 2021. (In Russ.) Available at: https://grls.rosminzdrav.ru (Access:14.01.2021)
23. Filippova N.V., Shuldyakov A. A., Barylynik Yu.B., et al. Metabolic support for patients with Mild (Pre-D ementia) Cognitive Impairment Post-C OVID-19. Experimental and Clinical Pharmacology. 2021; 84 (12): 3–8. (In Russ) doi 10.30906/0869–2092–2021–84–12–3–8
Review
For citations:
Shuldyakov A.A., Lyapina E.P., Smagina A.N., Lisko O.B. Metabolic support of antiviral therapy in patients with COVID-19. Experimental and Clinical Gastroenterology. 2022;(3):143-149. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-199-3-143-149
Views:
327
Email this article 